Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
2022 · Acta Pharmaceutica Sinica B · 58 citations
https://doi.org/10.1016/j.apsb.2022.10.023
Z
Zhengke Lian
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
8
Papers
214
Citations
5
h-index
5
i10-index
Zhengke Lian is an academic researcher from East China Normal University. The author has contributed to research in topics: Protein Kinase Regulation and GTPase Signaling & PI3K/AKT/mTOR signaling in cancer & Immune Cell Function and Interaction. The author has an h-index of 5, co-authored 7 publications.
ORCID: 0000-0001-8010-4616Papers by this author
worksLoss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons
2023 · Nature Communications · 27 citations
https://doi.org/10.1038/s41467-023-39943-y
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers
2025 · Cancer Cell · 12 citations
https://doi.org/10.1016/j.ccell.2025.07.006
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat